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Decades of sepsis research into a specific immune system-targeting adjunctive therapy
have not resulted in the discovery of an effective compound. Apart from antibiotics,
source control, resuscitation and organ support, not a single adjunctive treatment is
used in current clinical practice. The inability to determine the prevailing immunological
phenotype of patients and the related large heterogeneity of study populations are
regarded by many as the most important factors behind the disappointing results of
past clinical trials. While the therapeutic focus has long been on immunosuppressive
strategies, increased appreciation of the importance of sepsis-induced immunoparalysis
in causing morbidity and mortality in sepsis patients has resulted in a paradigm shift in
the sepsis research field towards strategies aimed at enhancing the immune response.
However, similar to immunosuppressive therapies, precision medicine is imperative for
future trials with immunostimulatory compounds to succeed. As such, identifying those
patients with a severely suppressed or hyperactive immune system who will most likely
benefit from either immunostimulatory or immunosuppressive therapy, and accurate
monitoring of both the immune and treatment response is crucial. This review provides
an overview of the challenges lying ahead on the path towards precision immunotherapy
for patients suffering from sepsis.
Keywords: sepsis, hyperinflammation, immunoparalysis, immunosuppressive therapy, immunostimulatory
therapy, biomarkers, precision medicine
INTRODUCTION
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response
to infection (1). It is the number one cause of death in the Intensive Care unit (ICU), and the
worldwide incidence of sepsis is estimated to exceed 30 million cases per year (2, 3). Despite
advances in ICU management and goal-directed interventions in the last decades, sepsis mortality
rates remain as high as 30% (4). In theWestern world alone, annually an estimated 6 million people
die of sepsis, representing more deaths than lung, breast and colon cancer together (5). In addition,
it is also one of themost expensive conditions encountered in hospitals, with annual costs exceeding
20 billion dollars in the US alone1. Despite these alarming facts, sepsis remains a relatively neglected
condition that is unknown to the general public.
1Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project Statistical Brief No 160. Available online
at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.pdf. 2013; August.
Peters van Ton et al. Precision Immunotherapy for Sepsis
In May 2017, the WHO adopted a resolution aimed to
improve the prevention, diagnosis, and management of sepsis2,
illustrating the urgency of the problem. The search for a specific
immune system-targeting adjunctive therapy has dominated
the sepsis research field for more than 4 decades, with the
disappointing result of dozens of negative trials and not a single
adjunctive treatment in current clinical use. Experts agree that
this is not due to the fact that the drugs tested are ineffective
per se, but rather to the inability to restrict treatment to selected
patient groups that may actually benefit from a specific type of
therapy (6–9). Not surprisingly, it is therefore also agreed upon
that precision medicine is imperative for future trials to succeed,
but accurate and reliable immunomonitoring is currently not
a reality (6, 8–10). For new therapies, it is paramount that
we do not make the same mistake that was previously made
for immunosuppressive treatments by advocating the use of
compounds in all sepsis patients. Instead, we should only target
patients who are truly hyperinflamed with immune suppressive
drugs and immunoparalyzed patients with immunostimulatory
compounds to avoid unnecessary risks of side effects in
patient groups with a lower chance of a therapeutic effect and
increase the chances of success in patient groups with a higher
likelihood of benefit. In addition to immunomodulatory therapy,
advocating personalized medicine is also relevant for other
promising sepsis treatments, for instance those targeting the
well-described metabolic dysfunction observed in these patients.
However this is beyond the scope of this review. This review
discusses whether we are targeting the right pathophysiological
immunological mechanisms and emphasizes the challenges that
lie ahead on the path towards precision immunotherapy for
septic patients.
Hyperinflammation in Sepsis
The proinflammatory response in sepsis is directed at eliminating
invading pathogens and involves leukocyte activation, cytokine
production, reactive oxygen species and protease release, and
complement and coagulation activation (9). An overzealous
hyperactive proinflammatory response may exert detrimental
effects for the host by eliciting high fevers, hypotension,
tachycardia, tachypnoea, coagulation disorders and organ failure,
the latter resulting from collateral tissue damage. Examples
of deleterious effects of hyperinflammation in various tissues
are illustrated in Figure 1. Pulmonary hyperinflammation
may lead to the development of acute respiratory distress
syndrome (ARDS), a life-threatening condition characterized
by unexplained respiratory failure through hypoxemia with
bilateral infiltrates of noncardiac origin (11). In the circulating
blood compartment hyperinflammation alters coagulation,
which may result in a relatively uncommon but fulminant
phenomenon called disseminated intravascular coagulation
(DIC) (12), which is characterized by simultaneous widespread
microvascular thrombosis and profuse bleeding. Capillary leak
and development of interstitial oedema are unfortunately very
common problems resulting from a systemic hyperinflammatory
2Available online at: https://www.global-sepsis-alliance.org/news/2017/5/26/wha-
adopts-resolution-on-sepsis. WHA resolution sepsis.
state, and have widespread cardiovascular effects such as
hypotension, tachycardia and in severe cases even septic shock
which results in more tissue damage. In the acute phase,
hyperinflammation in the brain may cause headaches, nausea,
apathy, somnolence or delirium. Furthermore it is suggested
that long-term effects such as cognitive decline and behavioral
changes can also be attributed to a hyperinflammatory state
(13). Other organs that are often affected by hyperinflammation
include the kidneys (acute kidney injury which frequently
requires renal replacement therapy), the intestines (paralytic
ileus), and the liver (liver failure with liver test abnormalities and
altered glycemic control).
From the 1970s until the turn of the century, it was
commonly assumed that sepsis mortality resulted exclusively
from this overzealous pro-inflammatory response. As a
consequence, therapeutic research in the sepsis field was
solely focused on dampening or preventing excessive
inflammation. However, all clinical trials to date investigating
immunosuppressive therapy in sepsis, including anti-endotoxin
(signaling) molecules, TLR-receptor antagonists, anti-cytokine
therapies (e.g., anti-TNF-α, IL-1RA etc.), and high dose
corticosteroids(14–24), have convincingly demonstrated
that inhibition of the immune response exerts no beneficial
effects in an unselected heterogeneous group of sepsis
patients.
Paradigm Shift in the Understanding of
Sepsis: The Detrimental Role of
Sepsis-Induced Immunoparalysis
In the last decade a paradigm shift in our understanding of
the immune derangements in sepsis has taken place (25). It is
increasingly recognized that, for many patients not excessive
immune activation, but rather immunosuppression, also known
as “sepsis-induced immunoparalysis,” is the overriding immune
dysfunction associated with high mortality and morbidity
(7, 25–29). The capacity of circulating leukocytes to release
proinflammatory cytokines is impaired during immunoparalysis
and apoptotic immune cell death is profoundly increased.
In contrast to necrotic cell death, which generally causes
stimulation of the immune system and enhanced defense against
microbes, apoptotic cell death results in anti-inflammatory
cytokine production, and cellular anergy (30–32). The majority
of cells lost through apoptosis in septic patients are lymphocytes
(33) and low absolute lymphocyte counts were shown to be
associated with mortality (34). Sepsis-induced immunoparalysis
renders patients unable to clear their primary infection and
more likely to develop secondary infections with opportunistic
bacteria or fungi (35) later on. This is in line with data
that the vast majority of septic patients do not die from the
initial pro-inflammatory hit, but at a later time point from
secondary or opportunistic infections in an immunosuppressed
state (35–38). More precisely: approximately a quarter of
sepsis patients die within 4 days. Of the remaining three-
quarter that survives, one third regains immunocompetence
and the mortality in this group is 10%. Two-thirds develops
immunoparalysis accounting for 65% of total mortality (10). The
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FIGURE 1 | Clinical consequences of hyperinflammation and immunoparalysis to selected tissues. ARDS, acute respiratory distress syndrome; LSEC, liver sinusoidal
endothelial cells; MDSC, myeloid-derived suppressor cells; RTEC, renal tubule epithelial cell; M-cell, microfold cell; TPN, total parenteral nutrition; HSPC,
hematopoietic stem and progenitor cells.
development of immunoparalysis appears to start simultaneously
with the proinflammatory response. The clinical relevance of
immunoparalysis is further illustrated by several observational
findings: (i) in patients who died from sepsis or septic shock, a
continuous septic focus was observed in 63 of the 71 patients
(89%) who were treated with antibiotics for more than 7 days
(39), (ii) during the late phase of sepsis, infections due to
opportunistic bacteria increase from 9 to 18% and Candida-
infections from 13 to 30% (35), and (iii) reactivation of latent
viruses was found in 43% of critically ill patients (40). Of
interest, detection rate of positive viral PCR results increased
with ICU length of stay and was associated with the development
of fungal and opportunistic bacterial infections. Importantly,
Epstein Barr virus and CMV PCR-titers in patients with a
bacterial sepsis was similar to those reported in stem-cell
and organ transplant patients, indicative of clinically relevant
immune suppression. These recent observational insights
indicate that sepsis-induced immunoparalysis accounts for the
majority of sepsis-related deaths. Although the importance
of immunoparalysis is increasingly recognized (28), there is
still lack of consensus that immunosuppression is a clinically
important phenomenon (41, 42). Nevertheless, combined
with the many disappointing trials on immunosuppressive
strategies, appreciation of the detrimental role of sepsis-
induced immunoparalysis (7, 25–29, 43) has led the sepsis
research field to focus more and more on ways to restore
the suppressed immune response through immunostimulatory
treatment (7, 25, 28, 29). This concept is appealing and the
treatments under investigation are most likely effective to reverse
immunoparalysis. However, in light of previous sepsis trials,
only patients with proven immunoparalysis should receive
immunostimulatory treatment to avoid unnecessary risks and
increase the chances of successful trials. However, methods
to identify patients with immunoparalysis and subsequent
therapeutic reversal of immunoparalysis are still in their
infancy.
Biomarkers to Stratify the Immune Status
in Sepsis Patients
Many cytokines, chemokines or other proteins have been studied
as potential biomarkers to characterize a hyperinflammatory
state in sepsis patients. Three pro-inflammatory cytokines,
namely tumor necrosis factor (TNF), interleukin-1β (IL-1β) and
interleukin-6 (IL-6) play a pivotal role in the initial response
of the innate immune system to injury or infection. These
three cytokines are, among others, crucial for activation of
endothelial cells, recruitment of leukocytes to the site, generation
of fever and other systemic symptoms, production of acute
phase reactants and induction of a shift in cell production
in the bone marrow (44). Nevertheless neither TNF or IL-1β
have emerged as reliable biomarker for hyperinflammation in
sepsis patients, potentially because they are elevated only for a
very short period of time in the initial phase of sepsis, when
patients may not yet have been admitted to the ICU. IL-6 has
been most extensively studied as a potential biomarker, with
the advantages of being elevated for a longer period of time
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and the availability of commercial bedside immunoassays (45).
Elevated levels of IL-6 in septic patients have been shown to
be associated with increased mortality (46, 47). However this
illustrates prognostic rather than diagnostic value and like most
cytokines, IL-6 is not specific for sepsis as increased levels
are observed in many inflammatory conditions. Moreover the
chemokines interleukin-8 (IL-8) and monocyte chemoattractant
protein-1 (MCP-1) have been shown to be superior to IL-6
for diagnosis of sepsis (48) and prediction of sepsis mortality
(49) respectively. The acute phase protein CRP has a high
sensitivity for detection of early onset sepsis (50), but its low
specificity is a major drawback for its use as a biomarker to
stratify the immune status in patients with sepsis. Procalcitonin
(PCT) is elevated in patients with invasive bacterial infections
(51). However it remains to be determined whether the
detection of bacteraemia with PCT can accurately distinguish
patients in a hyperinflammatiory state from patients with
immunoparalysis. Research on monocyte activation markers as
potential biomarkers of a hyperinflammatory state in sepsis
has identified a possible role for the soluble form of the
receptor for advanced glycation end-products (sRAGE). This
molecule may be considered as a receptor for danger associated
molecule patterns (DAMPs) and elevated levels were shown to
be associated with poor survival in severe sepsis (52). Despite
the numerous laboratory options illustrated above no accurate
single biomarker for hyperinflammation in sepsis is currently
used in clinical practice. As an alternative, a more clear clinical
example for a severe hyperinflammatory state is the macrophage
activation syndrome (MAS). This is defined as a fulminant
cytokine storm concurrent with hepatosplenomegaly, liver
dysfunction, hyperferritaemia, pancytopenia, and disseminated
intravascular coagulation (53). MAS is a serious complication
of sepsis and the clearly overriding hyperinflammatory state in
these patients, may provide opportunities for targeted application
of anti-inflammatory therapies, as discussed elsewhere in this
review.
Identification of patients with immunoparalysis is currently
based on HLA-DR expression on circulating monocytes and, to
a lesser degree, cytokine production of leukocytes stimulated ex
vivo with lipopolysaccharide (LPS, endotoxin) (54–57), although
the accuracy of these markers still lacks solid evidence. There are
no data on the predictive value on the individual patient level,
meaning that precision immunostimulatory treatment for sepsis
patients may not be feasible using the markers that are currently
advocated. The inability to restrict immunostimulatory treatment
to those patients who will actually most likely benefit from it may
result in another series of failed clinical trials, because beneficial
effects in immunoparalyzed patients will be offset by possible
harmful effects of these compounds in immunocompetent
patients. Several other markers of immunoparalysis are proposed
(25), based on the increasing knowledge of the pathophysiology
of immunoparalysis. These include expression of inhibitory
receptors like programmed death-1 (PD-1) and its ligand PD-L1
(58), cytotoxic T lymphocyte antigen-4 (CTLA-4) (59), and B
and T lymphocyte attenuator (BTLA) (60), molecules that play
a role in the exhaustion of lymphocytes. Furthermore, several
immunosuppressive lymphocyte subpopulations (including
T-regulatory cells) have been identified in patients suffering
from immunoparalysis (61). Moreover, epigenetic changes
were shown to be involved in immunoparalysis (54), revealing
that TLR-induced chromatin modifications are responsible for
transient silencing of tolerizable (T) genes (including those
encoding proinflammatory mediators), and for priming of non-
tolerizable (NT) genes (including those encoding antimicrobial
peptides). The T genes are transiently inactivated to prevent
pathology associated with excessive inflammation, while the NT
genes remain inducible to provide continuous protection from
infection and tissue repair. In addition, it was demonstrated
that negative TLR regulators such as IRAK-M and SHIP-1,
might also participate in the development of immunoparalysis
(62). However, the role of these relatively recently discovered
mechanisms in the pathogenesis of immunoparalysis is currently
unclear and clinical application as a biomarker is not yet feasible.
Understanding what causes the contrasting
hyperinflammatory and immunoparalyzed phenotypes observed
in sepsis—in other words: why do some patients exhibitit a
prevailing hyperinflammatory response while others display
immunoparalysis—would greatly aid biomarker discovery and
development. To the best of our knowledge, this is currently
unknown and a multifactorial etiology is likely, including host-
related factors such as age, gender, comorbidities, (epi)genetic
predisposition, microbiome composition, expression levels of
pattern-recognition receptors (PRRs), and release of DAMPs as
well as pathogen-related factors such as the type of pathogen, its
virulence and load, and quorum sensing.
Whether it concerns hyperinflammation or immunoparalysis,
it appears implausible that a single marker can act as a reliable
tool to guide immunomodulating therapy since biomarkers are
often related to one or a limited number of pathophysiological
mechanisms/pathways, while it has become clear that multiple
pathways are activated or inhibited at the same time in sepsis.
Therefore, it appears likely that a panel of markers reflects the
immune status of the sepsis patient more accurately.
Compartmentalization of the Immune
Response
At this moment, plasma markers or expression of molecules
in/on circulating immune cells are used to identify the immune
status of sepsis patients. However, due to compartmentalization
of the immune response and temporal differences in the immune
response between compartments, the phenotype of blood
leukocytes may not always be reflective of the current immune
status. There are several observations in support of this notion.
For instance, leukopenia is associated with a more pronounced
cytokine response in animal models of sepsis (63), indicating
limited importance of blood immune cells in producing
inflammatory mediators that are important for host defense.
Furthermore, the compartmentalized nature of the immune
response is supported by several results obtained by our group
in the human endotoxemia model. In this model endotoxin [also
known as lipopolysaccharide (LPS)] is administered to healthy
volunteers. Numerous studies have established that the immune
response to LPS captures many hallmarks of the immune
response observed in sepsis, including a phase of immune
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suppression. The latter phenomenon is known as “endotoxin
tolerance,” and characterized by a blunted inflammatory response
upon subsequent LPS challenges in vivo and ex vivo (64).
In keeping with the overlap between LPS-elicited effects and
clinical sepsis, endotoxin tolerance bears many similarities to
sepsis-induced immunoparalysis, including decreased cytokine
production by circulating leukocytes and attenuated mHLA-
DR expression (25, 27, 43). Therefore, endotoxin tolerance has
been used in translational research to model and investigate
treatments for sepsis-induced immunoparalysis, both in vitro
(65) and in vivo in humans (43). Strikingly, however, animal
studies have shown that despite a diminished immune response
indicating endotoxin tolerance, pathogen clearance and survival
upon a live bacterial challenge were improved in mice pre-
treated with LPS or other TLR ligands (66–69). It is unknown
whether these counterintuitive findings of an enhanced defense
against pathogens concurrent with endotoxin tolerance are also
present in humans, which should be an important focus for
future studies. Nevertheless, using the human endotoxemia
model we have demonstrated profound differences in ex vivo
and in vivo endotoxin tolerance kinetics. Both mHLA-DR
expression (43) and ex-vivo cytokine production by stimulated
leukocytes (70–72) are suppressed rapidly in the first hours
after endotoxin administration. The same studies show that
these markers normalize quickly afterwards and are restored
within 24 h after endotoxin administration, indicating that
functionality of circulating leukocytes can quickly recover in
the absence of ongoing inflammation. In contrast, the in vivo
response 1 to 2 weeks after the first endotoxin administration
is still severely blunted with an attenuation of pro-inflammatory
cytokine levels of approximately 60% compared to the first
endotoxin challenge (43, 70). From these observations it could be
concluded that parameters measured in the blood compartment
may not reflect the responsiveness of the immune system as a
whole, and that immune cells in other compartments than the
blood may likely better reflect the in vivo immune status at a
given moment in time. It is currently unknown whether this
discrepancy between the immune status of cells within the blood
compartment and the responsiveness of the in vivo immune
system is of clinical importance in sepsis patients, but tissue
resident macrophages and not circulating immune cells appear to
be predominantly responsible for the innate immune response in
sepsis. The relevance of organ-specific immunology and possible
consequences of a hyperinflammatory or immune-suppressed
state in several tissues (e.g., lungs, brain, adipose tissue, and
bonemarrow), are graphically presented in Figure 1 and outlined
below.
The lungs likely represent a highly relevant compartment
in the context of sepsis-induced hyperinflammation and
immunoparalysis. An exaggerated pro-inflammatory response
in the lungs may result in the life-threatening condition of
ARDS, requiring invasive mechanical ventilation and complex
respiratory therapy (73). In contrary, an immunosuppressed
response as observed in immunoparalysis increases the
susceptibility to secondary pulmonary infections. Along these
lines, hospital-acquired pneumonia represents the secondary
infection with the highest incidence observed in patients
that recovered from their initial sepsis (42, 74, 75). Alveolar
macrophages (AMs), as the first line of defense in the lungs,
play a key role in host defense. Whereas previous work
has demonstrated that AMs display a primed rather than
tolerant phenotype shortly (1.5–6 h) after LPS administration
in healthy volunteers (76), small studies in septic patients
point toward a tolerant phenotype of AMs (77, 78). This may
indicate that AMs switch from an initially primed phenotype
to a tolerant immunosuppressed phenotype at later stages
of disease progression, but these dynamics have yet to be
unraveled.
The brain was long regarded as an immune privileged
organ. The last decades of research have shown an important
immunological role of the brain in “non-immunological”
diseases like dementia, or psychiatric diseases. The so-called
microglial cells represent the resident macrophage population in
the brain, and account for 5–20% of the total glial cell population
of the brain. Research in healthy humans (79), animal data (80)
and post-mortem brain tissue of patients suffering from severe
systemic inflammation (81, 82) show that systemic inflammation
is a strong trigger that activates the resident microglia
(macrophages) of the brain. During systemic inflammation,
systemic inflammatory cytokines can enter brain tissue due to
a disrupted blood-brain barrier, but also through several parts
of the brain that lack a blood-brain barrier and directly activate
microglial cells. As a result, systemic inflammation may result
in an exaggerated neuroinflammatory cascade, which disrupts
normal homeostasis and cell function and may lead to neuronal
cell loss and cognitive deterioration (83, 84). Neuroinflammation
is thought to contribute to both acute sepsis-associated
encephalopathy, as well as long-term cognitive impairment
following critical illness. Previously, research into immune
responses of the brain during systemic inflammation was
impossible in living patients as the brain is a body compartment
not accessible for immunological research purposes without
using the invasive procedure of brain biopsies. Recently, several
innovative nuclear imaging tracers have been developed that can
quantitatively measure microglial activation in vivo, by targeting
the mitochondrial 18 kDa translocator protein (TSPO). Systemic
inflammation evoked during experimental human endotoxemia
was demonstrated to induce a 30–60% increase in microglial
activation in healthy volunteers 3 h after administration of
endotoxin (79). However, patients suffering from sepsis often
develop more prolonged periods of systemic inflammation and
a subsequent immunosuppressive state. The longitudinal effects
of endotoxemia and systemic inflammation on tissue resident
macrophage activation in the brain are unclear. A recent study in
mice showed that repeated subjection to systemic inflammation
on consecutive days induced a brain-specific training effect
initially, followed by reduced immunological response (immune
tolerance) of the brain after successive stimuli (85). In addition, a
recent human study in prostate surgery patients found decreased
microglial activity, measured by reduced microglial nuclear
ligand binding, 3–4 days postoperatively compared to baseline
(86). These results are the first indications that innate immunity
responses in the brain show signs of immunoparalysis, coinciding
with ex vivo and in vivo peripheral immunoparalysis.
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Recent studies have demonstrated that microbial components
can directly interact with hematopoietic stem and progenitor
cells (HSPCs) in the bone marrow via Toll-like receptors (TLRs)
expressed on HSPCs (87, 88). Microbial sensing by HSPCs
during infection may therefore influence hematopoietic cell
division and differentiation (88), and may ultimately impact
the efficacy of host defenses during infection. Moreover, septic
patients also exhibit reduced expression of HLA-DR in the
myeloid lineage of the bone marrow (89). To date, the
effects of systemic inflammation on HSPCs and their role in
development and maintenance of hyperinflammatory responses
or immunoparalysis in humans are unknown and represents an
exciting field for further study.
Adipose tissue is increasingly recognized as an immunological
organ, containing substantial amounts of adipose tissue
macrophages (ATMs) (90). Advances on the interplay between
metabolic and immunological research suggest an important
role of the immune system in metabolic conditions such as
obesity and diabetes mellitus (91). Lipids are important signaling
moieties for both immune responses and metabolic regulation.
Lipid infusion in vivo activates TLR4 signaling in adipocytes
and macrophages and enhances inflammatory gene expression
in adipose tissue (92) which adds to systemic insulin resistance.
During obesity, many immune cells infiltrate in adipose tissue
and promote a low-grade chronic inflammation (91). Conversely
is the role of adipose tissue during systemic inflammation
(e.g., sepsis) less well studied and human studies concerning
the dynamics of immune suppression/tolerance in ATMs are
completely lacking.
Future studies to characterize the immune response in other
body compartments are ongoing and necessary to further
characterize the in vivo immune status. These studies will
improve the insight in the mechanistics of the immunological
response during sepsis. It needs to be acknowledged that
guiding immunotherapy in clinical practice based on other
compartments than blood will however not be readily applicable,
since tissue-resident immunological markers are not easily
harvested or measured.
Novel Treatment Modalities in Sepsis
As mentioned earlier, previous therapeutic strategies for
sepsis patients have virtually exclusively focused on blocking
inflammation early in the course of sepsis. It has become
clear that a considerable proportion of sepsis patients do
not die from an overwhelming immune response and that
suppressing the immune system is not an effective strategy when
applied to all sepsis patients. Nevertheless, it is conceivable
that a subgroup of hyperinflamed patients may have benefited
from immunosuppressive therapy if they had been treated
according to their immune status. For example, the phase 3
trial evaluating the immune suppressant IL-1 receptor antagonist
(anakinra), performed more than 20 years ago, revealed no
effect on mortality in severe sepsis patients (21). However, a
post-hoc analysis of this study published many years later (93)
demonstrated a significantly lower mortality in a subgroup of
patients with MAS, which represented approximately 6% of the
enrolled sepsis patients. Although no definitive conclusions can
be drawn from this post-hoc analysis, it does suggest that a
specific subgroup of patients in a hyperinflammatory state could
benefit from immune suppressive therapy. Another argument
that therapy aimed at inhibition of the immune response should
not be discarded as of yet comes from a meta-analysis of 17
randomized controlled trials (almost 9,000 patients) evaluating
the effects of anti-tumor necrosis factor alpha (TNF-α) therapy
on mortality in severe sepsis. Despite negative results in each
individual study, the pooled odds ratio showed a significantly
reduced 28-day all cause mortality (94).
In the last decade, several immunostimulatory treatments
have shown promise in preclinical, as well as in case series and/or
small clinical studies (58, 95–104). Granulocyte-macrophage
colony stimulating factor (GM-CSF) and interferon-gamma
(IFNγ) are the most extensively investigated immunostimulatory
agents in sepsis. These compounds are potent stimulators of
myeloid cell function and they potentiate antigen presentation
capabilities through increasing mHLA-DR expression on and
pro-inflammatory cytokine production by monocytes (105,
106). A biomarker-guided (inclusion criterion mHLA-DR>8000
monoclonal antibodies per cell) randomized controlled trial
comparing GM-CSF to placebo showed that GM-CSF was
safe and effective in restoring monocytic immunocompetence.
Exploratory endpoints suggested that treated patients had shorter
duration of mechanical ventilation and a more swift decrease of
disease severity scores (95). Although a meta-analysis of 4 RCT’s
did not reveal a beneficial effect of GM-CSF on 28-day mortality,
patient numbers were probably too small for evaluation of this
endpoint (107). Treatment with IFNγ resulted in increased
mHLA-DR expression and restored TNFα production in a
human endotoxemia study, while further attenuating production
of the key anti-inflammatory cytokine IL-10 (43). Furthermore,
IFNγ showed promising results in several small case series,
for instance in patients suffering from opportunistic infections
not responding to regular treatment (97). Targeting lymphocyte
loss with apoptosis inhibitors has shown potential in animal
studies (108–110) but could theoretically result in uncontrolled
cell growth and organ injury as consequence of neutrophil
accumulation in tissues. Recently, the IRIS-7 randomized
controlled phase 2 trial was published, in which 27 patients
with septic shock were treated with recombinant human IL-
7 or placebo (111). In this trial, severe lymphopenia was
used to identify immunosuppressed patients. The anti-apoptotic
and lymphocyte function-enhancing cytokine IL-7 was well
tolerated and reversed sepsis-induced lymphopenia in these
patients. Naturally, statistical power to demonstrate clinically
relevant treatment effects was inadequate. Another attractive
immunostimulatory target is blockade of programmed death-1
(PD-1) or its ligand PD-L1. The PD-1 system is upregulated in
sepsis patients (37) and inhibition of the interaction between
PD-1 and its ligands promotes immune responses and antigen-
specific T-cell responses. In recent years, positive responses to
anti-PD-L1 therapy was demonstrated in the field of oncology
and given the many similarities between the immunosuppressive
mechanisms in cancer and sepsis, this could be promising
for the potential of PD-L1 antagonism in sepsis-induced
immunoparalysis. Unfortunately, a large multicenter trial was
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TABLE 1 | Examples of immunotherapy in sepsis.
Mechanism of action Summary of evidence
IMMUNOSUPPRESSIVE COMPOUNDS
anti-TNFα (various) Blocks pro-inflammatory effects of TNFα - Individual studies: no beneficial effects (94)
- Meta-analysis: reduced 28-day mortality, OR = 0.91 [95% CI 0.83–0.99] (94)
IL-1RA (anakinra) Blocks IL-1 receptor→ inhibits downstream
pro-inflammatory effects
- Study in unselected population of severe sepsis patients: no effect on mortality (21)
- Post-hoc analysis in subgroup of hyperinflamed patients with macrophage activation
syndrome: lower mortality (93)
IMMUNOSTIMULATORY COMPOUNDS
GM-CSF Enhances antigen presenting capacity and
pro-inflammatory cytokine production
- Meta-analysis: no effect on 28-day mortality in sepsis patients (probably underpowered)
(107)
- Biomarker-guided study (based on mHLA-DR expression): restoration of monocytic
immunocompetence, shorter duration of mechanical ventilation, and more swift
improvement of disease severity scores as exploratory endpoints (95)
IFN-γ Enhances antigen presenting capacity and
pro-inflammatory cytokine production
- Human endotoxemia model (mimicking sepsis-induced immunoparalysis): increased
mHLA-DR expression, restored TNFα production and further attenuated IL-10 production
(43)
- Case series in patients suffering from opportunistic infections not responding to regular
treatment: increased mHLA-DR expression and cytokine production by ex
vivo-stimulated leukocytes (97)
Recombinant human IL-7 Reduces apoptosis and enhances lymphocyte
function
- Phase 2 trial in septic shock patients with severe lymphopenia: safe, well-tolerated and
reversal of lymphopenia (111)
anti-PD-(L)1 Inhibits PD-1-PD-L1 interaction→ reduces
apoptosis and promotes T-cell responses
- Preclinical data in sepsis models: promising results (e.g., prevention of sepsis-induced
depletion of lymphocytes, increased TNF-α and IL-6 production, decreased IL-10
production, enhanced bacterial clearance, improved survival (102)
- Clinical data in the oncology field: effective, especially in advanced melanoma and
non-small cell lung cancer.
- No clinical trials in sepsis patients yet.
TNFα, tumor necrosis factor alpha; IL1RA, Interleukin-1 receptor antagonist; IL-1, interleukin-1; GM-CSF, granulocyte-macrophage colony stimulating factor; IFNγ , interferon gamma;
IL-7, interleukin-7; anti-PD-L1, programmed death-1 ligand antagonist; OR, odds ratio.
recently aborted by the sponsor due to other priorities (“CA209-
9FH, a randomized, double-blind, placebo-controlled, parallel-
group study to evaluate the efficacy and safety of nivolumab in
adults with sepsis”).Table 1 summarizes themechanism of action
and the (clinical) evidence thus far of the immunomodulatory
compounds described in this paragraph.
Fortunately, a number of clinical trials investigating these and
other immunostimulatory treatments are currently underway or
planned, illustrating the current interest and relevance of this
type of treatment for sepsis3. However, these either do not use
markers to enrich their patient population, or use biomarkers
of which the accuracy and robustness has not been sufficiently
demonstrated.
Summary and Future Directions
This review highlights the current challenges we face toward
precision immunotherapy for patients suffering from sepsis. The
urgent need for a patient-tailored approach in sepsis treatment
is clear, as 40 years of undirected sepsis trials have not resulted
in a single adjunctive therapy in current clinical use. Clearly,
we need tools to determine whether hyperinflammation or
immune suppression is the overriding immune dysfunction in a
specific patient. The paradigm shift in the understanding of the
pathophysiology of sepsis has resulted in increased interest for
3Clinicaltrials.gov registration no’s: NCT02797431, NCT02576457, NCT02361528,
NCT02867267.
promising immunostimulatory therapies, but it is key to identify
and select the appropriate patient population who may most
likely benefit from these compounds. So far, current circulating
biomarkers measured in blood have not been found sufficiently
robust for use in clinical practice. From a pathophysiological
perspective studies into other body compartments are warranted
to increase our understanding of the in vivo immune response in
patients with sepsis, but these insights will not be easily translated
in feasible methodology for clinical practice. As such, finding a
reliable biomarker to classify and monitor the overall immune
response in patients with sepsis and to guide and personalize
immunotherapy remains a holy grail.
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